Latest Female sexual arousal disorder Stories
CRANBURY, N.J., Feb. 20, 2015 /PRNewswire/ -- Palatin Technologies, Inc.
RALEIGH, N.C., Feb. 17, 2015 /PRNewswire/ -- Sprout Pharmaceuticals announced today that it has resubmitted a New Drug Application (NDA) to the U.S.
Triggers euro 2.5 Million (~$3 Million) Milestone Payment from Gedeon Richter CRANBURY, N.J., Dec. 29, 2014 /PRNewswire/ -- Palatin Technologies, Inc.
Survey Results Released After the FDA's First Drug Development Public Workshop on Female Sexual Dysfunction RED BANK, N.J., Nov.
Even the Score Campaign Calls on FDA to Approve Medical Treatment Options for Female Sexual Dysfunction WASHINGTON, Oct.
Group Highlights Benefits Of FDA-Approved Treatment Options For Quality Of Relationships As FDA Prepares For Landmark Workshop On FSD WASHINGTON, Oct.
CRANBURY, N.J. and BUDAPEST, Hungary, Sept. 3, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc.
Persistent gender inequity at FDA has led to 26 approved drugs for men, and ZERO for women WASHINGTON, June 4, 2014 /PRNewswire-USNewswire/ -- Highlighting a persistent gender inequity at the
Women treated with Tefina(TM) 0.6 mg reported a statistically significant increase in orgasms versus placebo TORONTO, May 28, 2014 /CNW/ -
Data show many women are not aware of hypoactive sexual desire disorder and often blame themselves for symptoms of low desire RED BANK, N.J., May 20, 2014 /PRNewswire/ -- Nearly one
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.